← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS › Centrally acting sympathomimetics
amfetamine
N06BA01
Forms & Strengths
- Tablet: 5 mg, 10 mg
- Extended-release capsule: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg
Adult Dosing
- Attention Deficit Hyperactivity Disorder (ADHD): Initial 5 mg orally once or twice daily, titrate by 5 mg at weekly intervals; max 40 mg/day
- Narcolepsy: 5 mg to 60 mg orally daily in divided doses
Pediatric Dosing
- ADHD (Children 3-5 years): Initial 2.5 mg orally daily, titrate by 2.5 mg weekly
- ADHD (Children 6 years and older): Initial 5 mg orally once or twice daily, titrate by 5 mg at weekly intervals; max 40 mg/day
Indications
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
Mechanism of Action
- Blocks reuptake of norepinephrine and dopamine into presynaptic neurons
- Increases release of monoamines into the extraneuronal space
Contraindications
- Known hypersensitivity to amphetamine products
- Advanced arteriosclerosis
- Symptomatic cardiovascular disease
- Moderate to severe hypertension
- Glaucoma
- History of substance use disorder
- Concurrent use of MAOIs or within 14 days
Adverse Reactions
- Insomnia
- Decreased appetite
- Weight loss
- Dry mouth
- Tachycardia
- Palpitations
- Elevated blood pressure
- Anxiety
- Restlessness
- Growth suppression in pediatric patients
Drug Interactions
- Monoamine Oxidase Inhibitors (MAOIs): Risk of hypertensive crisis
- Acidifying agents (e.g., ascorbic acid): Decrease amphetamine absorption and efficacy
- Alkalinizing agents (e.g., sodium bicarbonate): Increase amphetamine absorption and toxicity
- CYP2D6 inhibitors: May increase amphetamine exposure
- Serotonergic drugs: Increased risk of serotonin syndrome
Curated Content: Needs Vetting Before Put to Clinical Use